NIH Research Funding Opportunity: Zika Virus (ZIKV) Complications (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research on Zika virus (ZIKV) and its complications.

This FOA replaces PAR-16-106 which had used rolling application due dates to facilitate the rapid review and award of particularly urgent or time-sensitive projects.  The last date for submitting an application to PAR-16-106 is January 13, 2017.

ZIKV is a single-stranded RNA virus of the Flaviviridae family. It is transmitted to humans primarily through the bites of infected Aedes mosquitos, though both perinatal/in utero and sexual transmission have been reported.  Initially discovered in 1947, it has been reported in the Americas since 2014, with a major outbreak in Brazil starting in 2015.  Disease is seen in about 20% of infected people and is usually self-limited.  However, an association between ZIKV infection in pregnant women and severe microcephaly in their babies has been very concerning. Additionally the virus has been found in blood, fueling growing concerns about the risk of transfusion-transmission with particular concern over severe outcomes in at risk transfusion recipient populations such as women who are pregnant.

Complete details are available on:

https://grants.nih.gov/grants/guide/pa-files/PA-18-048.html

 

Recent Stories
Announcing the New Teratology Society Innovator Award

FDA Launches Predictive Toxicology Roadmap

PODCAST: Secrets of the Human Brain Revealed: Development, Disease & the Zika Virus